Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FGFR2 amp FGFR2 over exp |
| Therapy | Regorafenib |
| Indication/Tumor Type | stomach cancer |
| Response Type | no benefit |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR2 amp FGFR2 over exp | stomach cancer | no benefit | Regorafenib | Case Reports/Case Series | Actionable | In a Phase II trial, gastric cancer patients (n=3/35) with FGFR2 amplification and FGFR2 overexpression did not achieve an objective response when treated with Stivarga (regorafenib) (PMID: 33563752). | 33563752 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (33563752) | Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK. | Full reference... |